Cartesian Therapeutics
Update in progressRNAC (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company developing mRNA cell therapies for autoimmune diseases. Its lead candidate, Descartes-08, is an autologous mRNA CAR-T targeting BCMA, in Phase 2b for autoimmune diseases including generalized myasthenia gravis, SLE, and juvenile dermatomyositis (rare pediatric designation). Descartes-15, in Phase 1, is an autologous BCMA-directed mRNA CAR-T for multiple myeloma. Headquartered in Frederick, Maryland.
Company score
- Sentiment
- 0.30
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.19
- Governance
- 0.25
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.20
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. Carsten Brunn Ph.D.
- Employees75
- Websitewww.cartesiantherapeutics.com
Identifiers
- ISINUS8162121045
- FIGIBBG001J19Q25
- LEI529900NMN0LACZOL7C43
- CUSIP816212104
- CIK0001453687